Testosterone deficiency is known to affect men with increasing incidence throughout their lifespan. The clinical manifestations of testosterone deficiency, in turn, negatively impact men’s quality of life and perception of overall health. The interaction of chronic systemic disease and androgen deficiency represent an area for potential intervention. Here, we explore the topic of testosterone deficiency amongst men with end-stage organ failure requiring transplantation in order to elucidate the underlying pathophysiology of androgen deficiency of chronic disease and discuss whether intervention, including testosterone replacement and organ transplantation, improve patients’ outcomes and quality of life.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int. 1997;51:777–84.
Vidot H, Kline K, Cheng R, Finegan L, Lin A, Kempler E, et al. The relationship of obesity, nutritional status and muscle wasting in patients assessed for liver transplantation. Nutrients. 2019;11:2097.
Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M. et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829–37.
Evans M, Fryzek JP, Elinder C-G, Cohen SS, McLaughlin JK, Nyrén O. et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis. 2005;46:863–70.
Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV, Shoskes DA. Serum testosterone levels and mortality in men with CKD stages 3–4. Am J Kidney Dis. 2014;64:367–74.
Zhao JV, Schooling CM. The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK Biobank. BMC Med. 2020;18:122.
Filler G, Ramsaroop A, Stein R, Grant C, Marants R, So A. et al. Is testosterone detrimental to renal function?. Kidney Int Rep. 2016;1:306–10.
Metcalfe PD, Leslie JA, Campbell MT, Meldrum DR, Hile KL, Meldrum KK. Testosterone exacerbates obstructive renal injury by stimulating TNF-α production and increasing proapoptotic and profibrotic signaling. Am J Physiol-Endocrinol Metab. 2008;294:E435–43.
Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem. 2004;279:52282–92.
Müller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G. et al. Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int. 2002;62:1364–71.
Mahalik JR, Burns SM, Syzdek M. Masculinity and perceived normative health behaviors as predictors of men’s health behaviors. Soc Sci Med. 2007;64:2201–9.
Carrero JJ. Testosterone deficiency at the crossroads of cardiometabolic complications in CKD. Am J Kidney Dis. 2014;64:322–5.
LeRoith D, Danovitz G, Trestian S, Spitz IM. Dissociation of pituitary glycoprotein response to releasing hormones in chronic renal failure. Acta Endocrinol (Copenh). 1980;93:277–82.
Grossmann M, Hoermann R, Ng Tang Fui M, Zajac JD, Ierino FL, Roberts MA. Sex steroids levels in chronic kidney disease and kidney transplant recipients: associations with disease severity and prediction of mortality. Clin Endocrinol (Oxf). 2015;82:767–75.
Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. Br J Urol. 1996;78:635–8.
Pampa Saico S, Teruel Briones JL, Fernández Lucas M, Delgado Yagüe M, García Cano AM, Liaño García F. Treatment of the testosterone deficiency in hemodialysis patients. Preliminary results. Nefrolía (Engl Ed). 2016;36:462–3.
Chiang JM, Kaysen GA, Segal M, Chertow GM, Delgado C, Johansen KL. Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. Nephrol Dial Transpl. 2019;34:802–10.
Shoskes DA, Kerr H, Askar M, Goldfarb DA, Schold J. Low testosterone at time of transplantation is independently associated with poor patient and graft survival in male renal transplant recipients. J Urol. 2014;192:1168–71.
Reinhardt W, Kübber H, Dolff S, Benson S, Führer D, Tan S. Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. Endocrine. 2018;60:159–66.
Eckersten D, Giwercman A, Pihlsgård M, Bruun L, Christensson A. Impact of kidney transplantation on reproductive hormone levels in males: a longitudinal study. Nephron.2018;138:192–201.
Wang YJ, Wu JC, Lee SD, Tsai YT, Lo KJ. Gonadal dysfunction and changes in sex hormones in postnecrotic cirrhotic men: a matched study with alcoholic cirrhotic men. Hepatogastroenterology. 1991;38:531–4.
Baker HW, Burger HG, de Kretser DM, Dulmanis A, Hudson B, O’Connor S. et al. A study of the endocrine manifestations of hepatic cirrhosis. Q J Med. 1976;45:145–78.
Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Schölmerich J. et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol. 2003;15:495–501.
Jha SK, Kannan S. Serum prolactin in patients with liver disease in comparison with healthy adults: a preliminary cross-sectional study. Int J Appl Basic Med Res. 2016;6:8–10.
L’age M, Meinhold H, Wenzel KW, Schleusener H. Relations between serum levels of TSH, TBG, T4, T3, rT3 and various histologically classified chronic liver diseases. J Endocrinol Invest. 1980;3:379–83.
Wortsman J, Rosner W, Dufau ML. Abnormal testicular function in men with primary hypothyroidism. Am J Med. 1987;82:207–12.
Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol. 2016;65:906–13.
Gluud C, Bennett P, Dietrichson O, Johnsen SG, Ranek L, Svendsen LB, et al. Short-term parenteral and peroral testosterone administration in men with alcoholic cirrhosis. Scand J Gastroenterol. 1981;16:749–55.
Wells R. Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. Lancet. 1960;2:1416–9.
Yurci A, Yucesoy M, Unluhizarci K, Torun E, Gursoy S, Baskol M. et al. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. Clin Res Hepatol Gastroenterol. 2011;35:845–54.
Castro GRA, Coelho JCU, Parolin MB, Matias JEF, de Freitas ACT. Insulin-like growth factor I correlates with MELD and returns to normal level after liver transplantation. Ann Transpl. 2013;18:57–62.
Fenster LF. The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease. Ann Intern Med. 1966;65:738–44.
Floreani A, Mega A, Tizian L, Burra P, Boccagni P, Baldo V, et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int. 2001;12:749–54.
Handelsman DJ, Strasser S, McDonald JA, Conway AJ, McCaughan GW. Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. Clin Endocrinol. 1995;43:331–7.
Lenoir A, Fuertes E, Gómez-Real F, Leynaert B, Plaat DA van der, Jarvis D. Lung function changes over 8 years and testosterone markers in both sexes: UK Biobank. ERJ Open Research [Internet]. 2020 Jul [cited 2021 Jun 9];6. Available from: https://openres.ersjournals.com/content/6/3/00070-2020.
Karakou E, Glynos C, Samara KD, Msaouel P, Koutsilieris M, Vassilakopoulos T. Profile of endocrinological derangements affecting PSA values in patients with COPD. Vivo. 2013;27:641–9.
Pison CM, Cano NJ, Chérion C, Caron F, Court-Fortune I, Antonini M-T. et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax. 2011;66:953–60.
Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI. et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:870–8.
Baillargeon J, Urban RJ, Zhang W, Zaiden MF, Javed Z, Sheffield-Moore M. et al. Testosterone replacement therapy and hospitalization rates in men with COPD. Chron Respir Dis. 2019;16:1479972318793004
Card JW, Carey MA, Bradbury JA, DeGraff LM, Morgan DL, Moorman MP. et al. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006;177:621–30.
Voltz JW, Card JW, Carey MA, Degraff LM, Ferguson CD, Flake GP. et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008;39:45–52.
Márquez-Garbán DC, Chen H-W, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N. Y Acad Sci. 2009;1155:194–205.
Wu W-H, Yuan P, Zhang S-J, Jiang X, Wu C, Li Y. et al. Impact of pituitary–gonadal axis hormones on pulmonary arterial hypertension in men. Hypertension. 2018;72:151–8.
Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996;156:1173–7.
De Celis R, Pedrón-Nuevo N. Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive regimen. Arch Androl. 1999;42:9–20.
Tauchmanovà L, Carrano R, Sabbatini M, De Rosa M, Orio F, Palomba S. et al. Hypothalamic-pituitary-gonadal axis function after successful kidney transplantation in men and women. Hum Reprod. 2004;19:867–73.
Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res. 2004;19:1919–32.
Vigen R. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829.
Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.
Research C for DE and. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA [Internet]. 2019 Feb 9 [cited 2021 Oct 3]; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due.
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM. et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44.
Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA. et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018;200:423–32.
Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl. 2012;14:428–35.
Chen Q, Li X, Li J, Zhang W, Li H, Liu F. A comparative survey of sex hormones levels between elderly men with chronic heart failure and normal elderly subjects. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33:505–8.
Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821–5.
Hyde Z, Norman PE, Flicker L, Hankey GJ, McCaul KA, Almeida OP. et al. Elevated LH predicts ischaemic heart disease events in older men: the Health in Men Study. Eur J Endocrinol. 2011;164:569–77.
Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM. et al. Adverse events associated with testosterone administration. N. Engl J Med. 2010;363:109–22.
Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–8.
Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828–37.
Cheetham TC, An J, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP. et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177:491–9.
Corona G, Rastrelli G, Pasquale GD, Sforza A, Mannucci E, Maggi M. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018;15:820–38.
Gagliano-Jucá T, Basaria S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019;16:555–74.
Fleischer J, McMahon DJ, Hembree W, Addesso V, Longcope C, Shane E. Serum testosterone levels after cardiac transplantation. Transplantation. 2008;85:834–9.
Poglajen G, Jensterle M, Kravos N, Janež A, Vrtovec B. Low serum testosterone is associated with impaired graft function early after heart transplantation. Clin Transplant. 2017;31:e12970.
Caretta N, Feltrin G, Tarantini G, D’Agostino C, Tona F, Selice R. et al. Low serum testosterone as a new risk factor for chronic rejection in heart transplanted men. Transplantation. 2013;96:501–5.
Schofield RS, Hill JA, McGinn CJ, Aranda JM. Hormone therapy in men and risk of cardiac allograft rejection. J Heart Lung Transpl. 2002;21:493–5.
Tandler R, Kondruweit M, Fischlein T, Weyand M. Hormone therapy in men—increased risk of cardiac allograft rejection?. J Heart Lung Transplant. 2003;22:831
Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294:87–94.
Thirumavalavan N, Scovell JM, Lo E, Gondokusomo J, Khera M, Pastuszak AW, et al. Is treatment of hypogonadism safe for men after a solid organ transplant? Results from a retrospective controlled cohort study. Int J Impot Res [Internet]. 2020 Oct [cited 2021 Dec 9]; [5p.]. Epub 2020 Oct 7. Available from: https://doi.org/10.1038/s41443-020-00361-z.
Mechlin CW, Frankel J, McCullough A. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion. J Sex Med. 2014;11:254–61.
Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110:573–8.
Delu A, Kiltz RJ, Kuznetsov VA, Trussell JC. Clomiphene citrate improved testosterone and sperm concentration in hypogonadal males. Syst Biol Reprod Med. 2020;66:364–9.
Madhusoodanan V, Patel P, Lima TFN, Gondokusumo J, Lo E, Thirumavalavan N. et al. Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL. Int Braz J Urol. 2019;45:1008–12.
Zeyneloglu HB, Oktem M, Durak T. Male infertility after renal transplantation: achievement of pregnancy after intracytoplasmic sperm injection. Transpl Proc. 2005;37:3081–4.
Qiu Y, Yanase T, Hu H, Tanaka T, Nishi Y, Liu M. et al. Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology. 2010;151:3307–16.
Corcoran MP, Meydani M, Lichtenstein AH, Schaefer EJ, Dillard A, Lamon-Fava S. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol. 2010;206:217–24.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
1. Search terms:
Chronic kidney disease
Chronic liver disease
Chronic obstructive pulmonary disease
Congestive heart failure
About this article
Cite this article
Omil-Lima, D., Jesse, E., Gupta, K. et al. Testosterone deficiency in male organ transplant recipients. Int J Impot Res 34, 679–684 (2022). https://doi.org/10.1038/s41443-021-00513-9